AXA : Volatility should make a big comeback
| Entry price | Target | Stop-loss | Potential |
|---|
|
€18.42 |
€22 |
€17 |
+19.44% |
|---|
AXA shares are locked into a trading range. This phase will eventually have to end with a return of a clear trend.
Summary● In a short-term perspective, the company has interesting fundamentals.
● The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.55 for the 2020 fiscal year.
● Its low valuation, with P/E ratio at 10.02 and 6.89 for the ongoing fiscal year and 2021 respectively, makes the stock pretty attractive with regard to earnings multiples.
● This company will be of major interest to investors in search of a high dividend stock.
● Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
● The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
● The group usually releases earnings worse than estimated.
● For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.
AXA 
